Clinical trial · Observational
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
A Study to Evaluate a Remote, Decentralized, Direct-to-Patient Strategy for Clinical Research Engagement of Patients With Small Cell Lung Cancer (SCLC).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess self-reported preferences and needs of patients with SCLC, regarding choosing and accessing novel therapies in research or standard clinical care settings and supportive gaps in this area, through an initial and 3 month follow up survey.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small-cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- SCLC (primary de novo)
- description
- Blood collection, survey (baseline and Month 3)
- label
- SCLC (transformed)
- description
- Blood collection, survey (baseline and Month 3)
Primary outcomes (1)
- measure
- Feasibility of conducting trial in SCLC population
- timeFrame
- 12 months
- description
- Percentage of overall eligible subjects enrolled. Percentage of primary SCLC eligible subjects enrolled. Percentage of tSCLC eligible subjects enrolled. Percentage of SCLC eligible subjects enrolled compared to percentage of tSCLC eligible subjects enrolled. Percentage of primary SCLC enrolled subjects completed. Percentage of tSCLC enrolled subjects completed. Percentage of SCLC enrolled subjects completed compared to percentage of tSCLC enrolled subjects completed. Overall reasons for early termination. Reasons for early termination from trial in primary SCLC enrolled. Reasons for early termination from trial in tSCLC enrolled.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Men or women greater than or equal to 18 years of age at the time of consent 2. Ability to read, write and communicate in English 3. Provide voluntary consent to participate in this study, documented via a signed informed Consent Form (ICF) 4. Willing to provide clinical and medical information related to his/her cancer diagnoses to the study team as required 5. Willing to comply with the requirements of the study 6. Diagnosis of extensive stage primary SCLC or tSCLC Exclusion Criteria: 1. Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements 2. Subjects who previously enrolled to this study Note: Concurrent enrollment in other clinical trials is NOT exclusionary
References
Publications (0)
Data not yet available